{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"Einseitige Implantation des SPIRION Kehlkopfschrittmachers bei Patienten mit vorheriger permanenter Glottis-Erweiterung","eudractNumber":null,"id":8773,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06007144","phase":null,"recruitmentStart":"2023-08-18T08:53:12+02:00","shortTitle":"(GLP) Voroperationen am Kehlkopf","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A randomized, double-blind study to compare efficacy, pharmacokinetics, safety, and immunogenicity between ABP 234 and Keytruda (Pembrolizumab) in subjects with advanced or metastatic non-squamous non-small cell lung cancer","eudractNumber":"2023-508336-57","id":10260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06311721","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-09-30T08:09:58+02:00","shortTitle":"20210033","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A Phase IIIb, randomized, multicenter, open-label trial of&#160;Atezolizumab plus Bevacizumab<br />versus transarterial Chemoembolization (TACE)&#160;in intermediate-stage HepatoCellular Carcinoma","eudractNumber":"2020-004210-35","id":6680,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04803994","phase":{"id":"ph_10","name":"Phase IIIB"},"recruitmentStart":"2022-04-05T14:04:18+02:00","shortTitle":"ABC-HCC","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Preoperative FOLFOX versus postoperativ risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized Phase III Trial of the German Rectal Cancer Study Group.","eudractNumber":"2018-001356-35","id":5571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04495088","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-16T10:14:02+02:00","shortTitle":"ACO/ARO/AIO-18.2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin","eudractNumber":"2023-503696-15-00","id":10356,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06521190","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-06-01T09:46:32+02:00","shortTitle":"ACOU085 Study: Phase IIa trial on prevention of cisplatin-induced hearing loss in testicular cancer patients","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Adjuvant Dynamic marker - Adjusted Personalized Therapy \ncomparing adjuvant Elacestrant with standard endocrine \ntreatment in genomically and/or clinically high-risk ER+/HER2- \nearly breast cancer","eudractNumber":"2025-522484-15-00","id":12036,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT07242352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T11:08:21+02:00","shortTitle":"ADAPTela","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Psychosoziale Unterst&#252;tzungsbedarfe von Familien mit dem Li-Fraumeni-Syndrom (LFS) oder der Fanconi-An&#228;mie (FA)<div><br /><div>DRKS00034066</div><div><br /></div></div>","eudractNumber":null,"id":11241,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-05-19T10:04:20+02:00","shortTitle":"ADDRess - Subprojekt 2","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A randomized phase 3, double-blind, placebo-controlled study of elacestrant in patients with estrogen receptor - positive/ human groth factor receptor 2 negative, ESR1-mutaed, advanced breast cancer progressing to endocrine therapy and CDK 4/6 inhibitors","eudractNumber":"2024-512926-27-00","id":12013,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"ESR1 (Estrogen Receptor 1 Gen)","id":"mt_207"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06382948","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":null,"shortTitle":"ADELA","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<p class=\"MsoNormal\">ADOREG - Bundesweites prospektives Register zur Versorgungsforschung in der dermatologischen Onkologie<br /></p><p class=\"MsoNormal\"><br /></p><p class=\"MsoNormal\"><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></p>","eudractNumber":null,"id":6286,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau3","name":"Spinaliom (Plattenepithelkarzinom)"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2020-12-01T14:21:19+01:00","shortTitle":"ADOReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Comparison of two approved dialysis devices for treatment of metabolic or mixed acidosis in critically ill patients with acute kidney injury and indication for renal replacement therapy","eudractNumber":null,"id":11286,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05842369","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-17T08:35:20+02:00","shortTitle":"ADVOSversus CVVHD in metabolic or mixed acidosis","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}